1 Title: Performance evaluation of the Roche Elecsys Anti-SARS-CoV-2 S immunoassay 2 **Authors:** Elena Riester¹, Peter Findeisen², J. Kolja Hegel³, Michael Kabesch⁴, Andreas 3 Ambrosch⁵, Christopher M Rank⁶, Florina Langen⁶, Tina Laengin⁶, Christoph Niederhauser^{7,8} 4 5 6 Affiliations: ¹Labor Augsburg MVZ GmbH, Augsburg, Germany; ²MVZ Labor Limbach, Heidelberg, 7 Germany; ³Labor Berlin, Charité Vivantes Services GmbH, Berlin, Germany; ⁴University 8 9 Children's Hospital Regensburg (KUNO) at the Hospital St. Hedwig of the Order of St. John and the University Hospital, University of Regensburg, Germany; ⁵Institute for Laboratory 10 11 Medicine, Microbiology and Hygiene, Barmherzige Brüder Hospital, Regensburg, Germany; ⁶Roche Diagnostics GmbH, Penzberg, Germany; ⁷Interregionale Blood Transfusion Swiss Red 12 Cross, Bern, Switzerland; 8 Institute for Infectious Diseases (IFIK), University of Bern, Bern, 13 14 Switzerland 15 16 *Corresponding author 17 Christoph Niederhauser, Interregionale Blood Transfusion Swiss Red Cross, Murtenstrasse 18 133, 3008 Bern, Switzerland, Christoph.Niederhauser@itransfusion.ch 19 20 **Running Title:** Evaluation of the Elecsys Anti-SARS-CoV-2 S assay 21 **Key words:** SARS-CoV-2, spike protein, nucleocapsid protein, immunoassay, antibodies 22 23 Abstract Background: The Elecsys[®] Anti-SARS-CoV-2 S immunoassay (Roche Diagnostics 24 25 International Ltd, Rotkreuz, Switzerland) has been developed for the in vitro quantitative 26 detection of antibodies to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-27 2) spike (S) protein. We evaluated the performance of this assay using samples from seven 28 sites in Germany, Austria, and Switzerland. 29 30 Methods: Anonymized frozen, residual serum, or plasma samples from blood donation 31 centers or routine diagnostic testing were used for this study. For specificity and sensitivity 32 analyses, presumed negative samples collected before October 2019 and SARS-CoV-2 PCRconfirmed single or sequential samples were tested, respectively. The performance of the 33 34 Elecsys Anti-SARS-CoV-2 S immunoassay was also compared with other commercial 35 immunoassays.

36 37 Results: The overall specificity (n=7880 pre-pandemic samples) and sensitivity (n=240 PCR-38 positive samples [≥14 days post-PCR]) for the Elecsys Anti-SARS-CoV-2 S immunoassay 39 were 99.95% (95% confidence interval [CI]: 99.87-99.99) and 97.92% (95% CI: 95.21-40 99.32), respectively. Compared with seven other immunoassays, the Elecsys Anti-SARS-CoV-2 S assay had comparable or greater specificity and sensitivity. The Elecsys Anti-SARS-CoV-2 41 S immunoassay had significantly higher specificity compared with the LIAISON® SARS-CoV-2 42 S1/S2 IgG, ADVIA Centaur® SARS-CoV-2 Total, ARCHITECT SARS-CoV-2 IgG, iFlash-SARS-43 44 CoV-2 IgM, and EUROIMMUN Anti-SARS-CoV-2 IgG and IgA assays, and significantly higher 45 sensitivity (≥14 days post-PCR) compared with the ARCHITECT SARS-CoV-2 IqG, iFlash-46 SARS-CoV-2 IgG and IgM, and EUROIMMUN Anti-SARS-CoV-2 IgG assays. 47 48 Conclusion: The Elecsys Anti-SARS-CoV-2 S assay demonstrated a robust and favorable 49 performance across samples from multiple European sites, with a very high specificity and 50 sensitivity for the detection of anti-S antibodies.

51 Introduction 52 In December 2019 a novel coronavirus emerged (1), named severe acute respiratory 53 syndrome coronavirus 2 (SARS-CoV-2), which is the causative agent of the disease, COVID-54 19 (2, 3). SARS-CoV-2 is an enveloped, single-stranded RNA virus of the family 55 Coronaviridae; its genome encodes 16 nonstructural proteins and four structural proteins: 56 spike (S), envelope (E), membrane (M), and nucleocapsid (N) (4). The most prominent 57 protein component on the viral surface is the S glycoprotein – a large transmembrane 58 protein that assembles into trimers to form the distinctive surface spikes of coronaviruses (5, 59 6). Each S monomer consists of two subunits, S1 and S2, which mediate receptor binding 60 (via the receptor-binding domain [RBD] located in S1) and membrane fusion, respectively, 61 leading to entry into host cells (6-8). 62 63 Following infection with SARS-CoV-2, the host mounts an immune response against the 64 virus, including production of specific antibodies against viral antigens (9). Understanding 65 the dynamics of the antibody response to the virus is critical in establishing a relevant time 66 window to use for serology testing (9). Studies into the kinetics of antibodies to SARS-CoV-2 67 are rapidly emerging and, based on current evidence, both immunoglobulin M (IgM) and G 68 (IgG) antibodies have been detected as early as day 0 to 5 after symptom onset (10, 11). 69 The chronological order of appearance and levels of IqM and IqG appears to be highly 70 variable and often simultaneous (12-14). Several studies have observed median 71 seroconversion at day 10-13 after symptom onset for IqM and day 12-15 for IqG, with 72 maximum seroconversion for IgM, IgG, and total antibodies occurring at week 2-3, week 2-73 4, and around week 2, respectively (13-16). 74 75 Emergence of the COVID-19 pandemic has resulted in an urgent and unmet need to develop 76 reliable serological tests to determine past exposure to the virus and the seroprevalence in a 77 given population (17). This information is crucial to support diagnosis, contact tracing, 78 epidemiology studies, and vaccine development to enable characterization of pre-vaccination 79 immune status and vaccine-induced immune response (9, 18-20). There are currently 242 80 candidate SARS-CoV-2 vaccines in development (21) and, of these, 10 are currently in early, 81 limited, or fully approved use (status February 09, 2021) (22). The majority of the vaccines 82 in use are based on the S protein, with the goal of eliciting protective neutralizing 83 antibodies; the rest are based on whole inactivated SARS-CoV-2 (23, 24). Serology assays 84 are also needed for the identification of neutralizing antibodies from convalescent plasma 85 donors (25).

87 88

89

90

91 92

93

94

95

96

97 98

99

100

101

102

103

104

105

106

107108

109

110

111

112

113

114115

116

117

118

119

120

The Elecsys® Anti-SARS-CoV-2 S (Roche Diagnostics International Ltd, Rotkreuz, Switzerland) is an electrochemiluminescence immunoassay (ECLIA), which has been developed for the in vitro quantitative detection of antibodies, including IgG, against the SARS-CoV-2 S protein RBD in human serum and plasma (26). The objective of this multicenter European study was to evaluate the specificity and sensitivity of the Elecsys Anti-SARS-CoV-2 S immunoassay using pre-pandemic samples (from routine diagnostics or blood donation) and PCR-positive samples, respectively, as well as compare the performance of this quantitative test with other commercially available immunoassays in terms of specificity and sensitivity. Materials and methods Study design The study was executed from August 17, 2020 to September 1, 2020 with samples tested at four European sites: Labor Augsburg MVZ GmbH, Augsburg, Germany; MVZ Labor Dr. Limbach & Kollegen GbR, Heidelberg, Germany; Interregionale Blutspende SRK AG (SRK Bern), Bern, Switzerland; and Krankenhaus Barmherzige Brüder, Regensburg, Germany. Samples were collected from those four sites, as well as from three additional sites: Labor Berlin - Charité Vivantes GmbH, Berlin, Germany; Tirol Kliniken, Innsbruck, Austria; and Deutsches Rotes Kreuz Blutspendedienst West, Hagen, Germany. Samples from Augsburg and Heidelberg included those referred to the respective study site by physicians. Heidelberg also tested samples from employees and hospitalized patients, including a subset from patients receiving dialysis. All samples provided by the study site in Berlin were collected from hospitalized patients, including a subset from patients monitored in the intensive care unit (ICU). Samples tested in Regensburg were taken from employees and pediatric patients referred to the site by physicians. These samples were collected and tested in accordance with applicable regulations, including relevant European Union directives and regulations, and the principles of the Declaration of Helsinki. All samples from Augsburg, Heidelberg, Berlin, and Hagen were anonymized. A statement was obtained from the Ethics Committee (EC) of the Landesärztekammer Bayern confirming that there are no objections to the use of anonymized leftover samples. From the internal EC at the study site in Bern (Switzerland) a

122

123124

125

126

127

128129

130

131

132

133

134

135

136

137

138139

140

141142

143

144

145

146147

148

149

150

151

152

153

154

155

waiver was received and from the internal EC at the study site in Innsbruck (Austria) an approval was received. For Regensburg (Germany), EC approvals were already in place, amendments were submitted to notify the EC about Elecsys Anti-SARS-CoV-2 S testing. At Augsburg, Heidelberg, and Bern the assays were performed on the cobas e 801 analyzer (Roche Diagnostics International Ltd, Rotkreuz, Switzerland), whereas at Regensburg the assays were performed on the cobas e 601 analyzer (Roche Diagnostics International Ltd, Rotkreuz, Switzerland). Serum and plasma samples Anonymized frozen, residual samples from blood donation centers or routine laboratory diagnostics, as well as banked samples, were used for this study. For specificity analysis of the Elecsys Anti-SARS-CoV-2 S assay, 7880 presumed negative samples (5056 blood donor and 2824 diagnostic routine samples) that were collected before October 2019 were tested. The diagnostic routine cohort included samples from pregnancy screening and pediatrics. For the sensitivity analysis of the Elecsys Anti-SARS-CoV-2 S assay, 827 PCR-confirmed single or seguential samples from 272 different patients, with known time difference between blood draw and positive PCR test, were tested. Of these presumed negative and PCR-confirmed samples, 7903 were tested on the commercially available Elecsys[®] Anti-SARS-CoV-2 assay (Roche Diagnostics International Ltd, Rotkreuz, Switzerland) (27). Additionally, a number of these samples were tested on other commercially available assays: LIAISON® SARS-CoV-2 S1/S2 IgG (DiaSorin) (28), 2052 samples; EUROIMMUN Anti-SARS-CoV-2 IgG (29) and IgA assays (EUROIMMUN) (30), 1618 and 1624 samples, respectively; ARCHITECT SARS-CoV-2 IgG (Abbott) (31), 3068 samples; ADVIA Centaur® SARS-CoV-2 Total (Siemens Healthineers) (32), 1064 samples; iFlash-SARS-CoV-2 IgG and IgM assays (Shenzhen YHLO Biotech Co) (33), both 1062 samples. Elecsys Anti-SARS-CoV-2 S assay The Elecsys Anti-SARS-CoV-2 S immunoassay is a quantitative ECLIA that detects highaffinity antibodies to the SARS-CoV-2 S protein RBD and has a low risk of detecting weakly cross-reactive and unspecific antibodies. Results are automatically reported as the analyte concentration of each sample in U/mL, with <0.80 U/mL interpreted as negative for anti-SARS-CoV-2 S antibodies and ≥0.80 U/mL interpreted as positive for anti-SARS-CoV-2 S antibodies (Roche Diagnostics GmbH. Elecsys Anti-SARS-CoV-2 S assay method sheet. 2020; version 01) (26).

157

158

159

160 161

162

163

164

165

166 167

168

169

170

171

172

173174

175

176

177

178

179

180

181182

183

184

185

186 187

188

189

190

Comparator assays Specimens were analyzed using eight comparator immunoassays according to the manufacturer's instructions. Interpretation of results was performed according to the manufacturer's instructions. The Elecsys Anti-SARS-CoV-2 assay is an ECLIA for the *in vitro* qualitative detection of antibodies, including IgG, against SARS-CoV-2, using a recombinant protein representing the nucleocapsid (N) antigen (27). Results are automatically calculated in the form of a cutoff index (COI), with COI values < 1.0 interpreted as non-reactive (negative) for anti-SARS-CoV-2 N antibodies and ≥ 1.0 as reactive (positive) for anti-SARS-CoV-2 N antibodies (27). The LIAISON SARS-CoV-2 S1/S2 IgG assay is an indirect chemiluminescence immunoassay (CLIA) for the quantitative detection of IgG anti-S1 and IgG anti-S2 antibodies to SARS-CoV-2 (28). Results are automatically calculated, with antibody concentrations expressed as arbitrary units (AU/mL). Concentrations of <12.0 AU/mL are interpreted as negative, \geq 12.0 to <15.0 AU/mL are interpreted as equivocal, and ≥15.0 AU/mL are interpreted as positive (28). Equivocal values are referred to as 'gray zone' results. The EUROIMMUN Anti-SARS-CoV-2 IgG and IgA assays are separate enzyme-linked immunosorbent assay (ELISAs) that detect IgG or IgA anti-S1 antibodies to SARS-CoV-2 (29, 30). Results are evaluated semi-quantitatively by calculation of a ratio in which the absorbance values of the controls or patient samples are related to the absorbance value of the calibrator (29, 30). For both assays, ratio results <0.8 are interpreted as negative, \geq 0.8 to <1.1 are borderline, and ≥ 1.1 are positive (29, 30). Borderline values are referred to as 'gray zone' results. The ARCHITECT SARS-CoV-2 IqG assay is a chemiluminescent microparticle immunoassay (CMIA) used for the qualitative detection of IgG antibodies against the N antigen (31). Results are expressed in signal-to-cutoff (S/CO) values, with <1.4 results interpreted as negative and ≥ 1.4 results interpreted as positive (31). The ADVIA Centaur SARS-CoV-2 Total assay is a CLIA intended for the qualitative detection of antibodies against the RBD of the S1 protein (32). Results are reported in index values, with <1.0 interpreted as non-reactive (negative) for anti-SARS-CoV-2 antibodies and ≥ 1.0 interpreted as reactive (positive) for anti-SARS-CoV-2 antibodies (32).

193

194

195

196 197

198

199

200

201

202

203

204

205

206

207

208

209

210211

212

213

214

215

216

217

218

219220

221

222

223

224

225

The iFlash-SARS-CoV-2 IgM and IgG assays (33) are separate CLIAs used for the qualitative detection of IqM or IqG against the S and N proteins. The iFlash system automatically calculates the analytic concentration of each sample, with <10 AU/mL interpreted as nonreactive and ≥10 AU/mL interpreted as reactive for anti-SARS-CoV-2 IgM or IgG antibodies. Statistical analysis Sample size estimations for specificity and sensitivity analyses were based on formulae proposed previously (34). Assuming specificities between 0.998 and 0.999 and a sensitivity of 0.999, samples sizes of 1698 to 20964 and 32 to 50 respectively, would be required to obtain a significance level of 0.05 and a power of 0.8. For specificity and sensitivity calculations, point estimates and two-sided 95% confidence intervals (CIs) using the exact method were computed employing R version 3.4.0 (35). In the sensitivity evaluation, assay results were assigned to the respective week after positive PCR result. In the comparison with other commercially available assays, only samples with paired measurements were included in the respective analyses. For the differences in estimated specificities and sensitivities between Elecsys Anti-SARS-CoV-2 S assay and the comparator assays, twosided 95% Wald CIs were calculated as previously recommended (36). If these CIs did not include zero, differences were considered as statistically significant. Data availability Qualified researchers may request access to individual patient level data through the clinical study data request platform (https://vivli.org/). Further details on Roche's criteria for eligible studies are available here: https://vivli.org/members/ourmembers/. For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here: https://www.roche.com/research and development/who we are how we work/clinical tri als/our commitment to data sharing.htm. Results Overall performance of the Elecsys Anti-SARS-CoV-2 S assay Specificity in different target cohorts Specificity of the Elecsys Anti-SARS-CoV-2 S assay was evaluated at three European sites (with samples from five European sites) using 7880 evaluable residual samples from blood donors and routine diagnostic testing; all of which were collected before October 2019 and

227

228

229

230

231

232

233

234235

236

237

238

239

240

241

242

243

244

245

246

247248

249

250

251

252

253

254255

256

257

258

259

260

presumed negative for SARS-CoV-2 antibodies. The overall specificity for all samples was 99.95% (95% CI: 99.87-99.99) (Table 1). There were four samples with reactive results of 1.790 U/mL, 0.900 U/mL, 0.870 U/mL, and 1.130 U/mL. Three of these reactive samples were from blood donor samples, of which one was collected in March 2016 (influenza season) at Innsbruck, Austria and two were collected in July/August 2018 (outside influenza season) at Bern, Switzerland (Table 1). There was no statistically significant difference in specificity between blood donor samples collected during or outside influenza season. The other reactive sample was from the pregnancy screening cohort in Augsburg (Table 1). Sensitivity in different target cohorts In total, 827 evaluable single and sequential samples from 272 SARS-CoV-2 PCR-confirmed patients were evaluated at three European sites (with samples from four European sites). The time span of samples collected after positive PCR was between day 0 and day 120. For subjects with sequential blood draws with more than one sample per time interval, only the result of the last blood draw per given time interval was used for the respective sensitivity calculation. The sensitivity of the Elecsys Anti-SARS-CoV-2 S assay ≥14 days post-PCR (n=240) was 97.92% (95% CI: 95.21-99.32) (Table 2a). The resulting site-specific sensitivities for Augsburg, Berlin, Heidelberg, and Regensburg samples collected ≥ 14 days post-PCR confirmation were 100.00% (95% CI: 95.89-100.00), 100.00% (95% CI: 91.40-100.00), 98.72% (95% CI: 93.06–99.97%), and 87.88% (95% CI: 71.80–96.60), respectively (Table 2b). Visualization of seroconversions and/or titer visualization For all subjects with at least two sequential blood draws, trajectories were plotted to visualize antibody titer development from day 0 to 78 post-PCR-positive test (Figure 1). Most trajectories show a rapid increase in antibody titer and no considerable decline of antibody titer can be seen for the early and later blood draws. Once detected reactive, none of the subsequent samples drawn per subject showed a decline of titer below the cutoff. Comparison with Elecsys Anti-SARS-CoV-2 assay A direct method comparison between the Elecsys Anti-SARS-CoV-2 S assay and the commercially available Elecsys Anti-SARS-CoV-2 assay was performed. This included a total of 7903 samples comprising both confirmed positive samples from sensitivity testing and presumed positive samples with at least one positive antibody result (n=1011), as well as presumed negative samples from specificity testing cohort samples (n= 6892: n=4068 blood

261 donors; n=2824 routine diagnostic). For all samples, the overall percent agreement (OPA) 262 between the Elecsys Anti-SARS-CoV-2 S assay and the Elecsys Anti-SARS-CoV-2 assay was 263 99.30% (95% CI: 99.10-99.48) (Table S1a). For presumed negative samples and confirmed 264 positive samples, the negative percent agreement (NPA) and positive percent agreement 265 (PPA), respectively, between the S- and N-assays were >99% (Table S1b-c). 266 267 Comparison with other commercially available assays 268 The performance of the Elecsys Anti-SARS-CoV-2 S immunoassay was compared with seven 269 other commercially available SARS-CoV-2 assays, and sensitivity and specificity results, 270 along with percent agreement, were recorded. 271 272 The OPA between the Elecsys Anti-SARS-CoV-2 S assay and other comparator tests was 273 recorded (Table S2). The Elecsys Anti-SARS-CoV-2 S test had the highest OPA with the 274 ARCHITECT SARS-CoV-2 IgG (N-assay), at 99.19% (95% CI: 98.80–99.47), and the lowest 275 OPA with the ADVIA Centaur SARS-CoV-2 Total (S-assay), at 88.25% (95% CI: 86.16-276 90.13) (Table S2). 277 278 Specificity 279 The specificity of the Elecsys Anti-SARS-CoV-2 S assay was comparable or higher than the 280 specificity of all tested comparator assays (Table 3). The specificity of the Elecsys Anti-281 SARS-CoV-2 S test was significantly higher compared with the LIAISON SARS-CoV-2 S1/S2 282 IgG, ADVIA Centaur SARS-CoV-2 Total, ARCHITECT SARS-CoV-2 IgG, iFlash-SARS-CoV-2 283 IgM, and EUROIMMUN Anti-SARS-CoV-2 IgG and IgA assays (Table S3a). No statistically 284 significant difference was observed between the specificity of the Elecsys Anti-SARS-CoV-2 S 285 assay compared with the iFlash-SARS-CoV-2 IgG assay (Table S3a). 286 287 Sensitivity 288 The sensitivity of the Elecsys Anti-SARS-CoV-2 S assay for detecting seropositive results was 289 compared with six comparator assays; analysis compared with the LIAISON SARS-CoV-2 290 S1/S2 IgG test could not be performed due to a small sample size. Sensitivity was recorded 291 for samples collected between 0-6, 7-13, and ≥ 14 days post-PCR-positive test. The 292 sensitivity of the Elecsys Anti-SARS-CoV-2 S assay was equal to or higher than the sensitivity 293 for all tested IqM, IqG, and total antibody assays at all time intervals (Table 4). The 294 EUROIMMUN Anti-SARS-CoV-2 IgA assay showed a higher sensitivity in the 0–6 and 7–13 295 days post-PCR time intervals and a lower sensitivity in the ≥14 days post-PCR time interval

297

298

299

300 301

302

303

304

305

306

307

308

309

310311

312

313

314

315

316

317

318

319

320

321

322323

324

325

326

327

328

329

330

compared with the Elecsys Anti-SARS-CoV-2 S assay (Table 4). The sensitivity of the Elecsys Anti-SARS-CoV-2 S assay at detecting antibodies ≥ 14 days post-PCR was significantly higher compared with the ARCHITECT SARS-CoV-2 IgG, iFlash-SARS-CoV-2 IgG and IgM, and EUROIMMUN Anti-SARS-CoV-2 IgG assays (Table S3b). Discussion Due to the COVID-19 pandemic, there is a pressing need to develop highly specific and sensitive serology tests to assist with the diagnosis of, and to reveal past exposure to, the SARS-CoV-2 virus (17), as well as to support the development of vaccines through distinguishing natural infection-induced immunity from vaccine-induced immunity (9, 18). This was the first multicenter study to demonstrate the performance of the automated Elecsys Anti-SARS-CoV-2 S immunoassay, which detects antibodies against the SARS-CoV-2 S protein RBD. Antibodies against the RBD have previously been shown to correlate strongly with protective neutralizing antibodies (37). The results from our study revealed that the Elecsys Anti-SARS-CoV-2 S immunoassay displays a robust and favorable performance under routine conditions at multiple sites in Europe, with a very high specificity (99.95%) and sensitivity (97.92%) for the detection of anti-S antibodies. The point estimates for specificity and sensitivity are comparable to the values reported in the package insert of the Elecsys Anti-SARS-CoV-2 S assay (99,98% and 98.8%, respectively) (26). In addition, the Elecsys Anti-SARS-CoV-2 S assay showed a performance comparable with the commercially available Elecsys Anti-SARS-CoV-2 (Nassay), with 95% CIs that overlap (99.69–99.88% for specificity and 97.0–100% for sensitivity); both assays had a very high overall percent agreement. The Elecsys Anti-SARS-CoV-2 assay has a previously reported specificity and sensitivity ≥14 days post-confirmation of 99.8% and 99.5%, respectively (38). The overall specificity of >99.9% determined in this study demonstrated that the Elecsys Anti-SARS-CoV-2 S is a highly specific assay for the detection of antibodies against SARS-CoV-2. Notably, this analysis included 2424 samples from pregnant women and pediatric populations. The availability of an accurate SARS-CoV-2 serology assay is particularly important for the pregnant population, considering the changes in the immune system that occur during pregnancy, which may increase the woman's susceptibility to severe infection (39). Additionally, an antibody assay with a high specificity is imperative to reduce the risk of false-positive results, which may inaccurately indicate a past SARS-CoV-2 infection (40).

333

334

335

336

337

338

339340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355 356

357

358

359

360

361 362

363

364

365

The Elecsys Anti-SARS-CoV-2 S immunoassay demonstrated good specificity and sensitivity in direct comparison with other commercially available assays; both performance measurements were equal to or greater than those for all other evaluated comparator assays. These other assays have also been assessed in previous studies (17, 41-44). However, it is important to note that, for a direct comparison of sensitivity, the available assays differ with respect to assay designs (e.g. antibody classes used) as well as the targets (anti-N and anti-S) that they detect. A multicenter comparison of seven serology assays, including the Elecsys Anti-SARS-CoV-2 assay, revealed a subpopulation of PCR-confirmed SARS-CoV-2 individuals who were persistently seronegative, which represents a proportion of patients that may be at risk for re-infection (45). Within the group of PCR-confirmed samples in our study, for which there was at least one S and one N antibody result from another comparator assay, there were samples from five patients all of which had a reactive Elecsys Anti-SARS-CoV-2 S test result, a reactive or 'gray zone' EUROIMMUN test result and a reactive ADVIA Centaur test result (S-assays), and a non-reactive Elecsys Anti-SARS-CoV-2 and ARCHITECT SARS-CoV-2 IgG test result (N-assays). There was only one sample that was commonly non-reactive in all Sbased assays and reactive in all N-based assays. However, the blood draw was taken very early, at the same day as the PCR was done, and the follow-up sample was reactive with the Elecsys Anti-SARS-CoV-2 S assay. Data indicating differences in the kinetics of serology assays are ambiguous and there is little difference in the timing of these responses (42, 46-49). However, differences between N- and S- antigen-based assays should be taken into consideration when interpreting results. A major strength of this study is the large cohort of presumed negative samples from multiple sites used to determine the specificity of the assay, as well as the multiple method comparison analyses performed and the various population cohorts used, with samples from pediatric and pregnant woman. Further studies should be performed to determine the sensitivity of the Elecsys Anti-SARS-CoV-2 S immunoassay on a larger sample group. Conclusion This study demonstrated the performance of the Elecsys Anti-SARS-CoV-2 S immunoassay, with a very high specificity of 99.95% and sensitivity of 97.92% in samples ≥14 days post-PCR confirmation, which was equal to or greater than the performance of seven other

367

368

369

370371

372

373374

375

376

377

378

379

380 381

382

383

384

385

386

387

388

389

390

commercially available immunoassays. Therefore, these data support the use of the Elecsys Anti-SARS-CoV-2 S immunoassay for reliable identification of past exposure to SARS-CoV-2 in various populations, and highlight the potential for the use of this assay in determining immune status during vaccine efficacy studies. Funding This study was funded by Roche Diagnostics GmbH (Mannheim, Germany). **Conflicts of interest** ER and AA report grants from Roche Diagnostics, during the conduct of the study and personal fees from Roche Diagnostics (honoraria for lectures), outside the submitted work. MK reports non-financial support from Roche Diagnostics, during the conduct of the study. CN, PF and JKH have nothing to disclose. FL, CMR, and TL are employees of Roche Diagnostics GmbH. Acknowledgements The authors would like to acknowledge: Kathrin Schoenfeld (Roche Diagnostics) for her role in study conceptualization, study management, interpretation of analysis, and further critical input; Michael Laimighofer (Roche Diagnostics) for his role in database generation and data validation, statistical analysis plan, and formal analysis; and Sigrid Reichhuber and Janina Edion (Roche Diagnostics) for their role in investigational site management, data acquisition, and study monitoring. Medical writing support was provided by Katie Farrant, Elements Communications Ltd, Westerham, UK and was funded by Roche Diagnostics International Ltd, Rotkreuz, Switzerland. ELECSYS and COBAS E are trademarks of Roche Diagnostics. All other product names and trademarks are the property of their respective owners.

References

- 392 1. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, Xing F, Liu J, Yip CC, Poon RW, Tsoi
- 393 HW, Lo SK, Chan KH, Poon VK, Chan WM, Ip JD, Cai JP, Cheng VC, Chen H, Hui CK,
- Yuen KY. 2020. A familial cluster of pneumonia associated with the 2019 novel
- coronavirus indicating person-to-person transmission: a study of a family cluster.
- 396 Lancet 395:514-523.
- 397 2. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, Hu Y, Tao ZW, Tian JH, Pei YY,
- Yuan ML, Zhang YL, Dai FH, Liu Y, Wang QM, Zheng JJ, Xu L, Holmes EC, Zhang YZ.
- 399 2020. A new coronavirus associated with human respiratory disease in China. Nature
- 400 579:265–269.
- 401 3. World Health Organization. 2020. WHO Director-General's remarks at the media
- 402 briefing on 2019-nCoV on 11 February 2020.
- 403 https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-
- 404 <u>media-briefing-on-2019-ncov-on-11-february-2020</u>. Accessed February 26 2021.
- 405 4. Naqvi AAT, Fatima K, Mohammad T, Fatima U, Singh IK, Singh A, Atif SM, Hariprasad
- G, Hasan GM, Hassan MI. 2020. Insights into SARS-CoV-2 genome, structure,
- evolution, pathogenesis and therapies: Structural genomics approach. Biochim
- 408 Biophys Acta Mol Basis Dis 1866:165878.
- 409 5. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. 2020. Structure,
- 410 function, and antigenicity of the SARS-CoV-2 spike glycoprotein, Cell 181;281–292
- 411 e6.
- 412 6. Tang T, Bidon M, Jaimes JA, Whittaker GR, Daniel S. 2020. Coronavirus membrane
- fusion mechanism offers a potential target for antiviral development. Antiviral Res
- 414 178:104792.
- 415 7. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, Graham BS,
- 416 McLellan JS. 2020. Cryo-EM structure of the 2019-nCoV spike in the prefusion
- 417 conformation. Science 367:1260–1263.
- 418 8. Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, Guo L, Guo R, Chen T, Hu J, Xiang Z, Mu Z,
- Chen X, Chen J, Hu K, Jin Q, Wang J, Qian Z. 2020. Characterization of spike
- 420 glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with
- 421 SARS-CoV. Nat Commun 11:1620.
- 422 9. Galipeau Y, Greig M, Liu G, Driedger M, Langlois MA. 2020. Humoral responses and
- 423 serological assays in SARS-CoV-2 infections. Front Immunol 11:610688.
- 424 10. Liu W, Liu L, Kou G, Zheng Y, Ding Y, Ni W, Wang Q, Tan L, Wu W, Tang S, Xiong Z,
- 425 Zheng S. 2020. Evaluation of nucleocapsid and spike protein-based enzyme-linked

- 426 immunosorbent assays for detecting antibodies against SARS-CoV-2. J Clin Microbiol
- 427 58.
- 428 11. Guo L, Ren L, Yang S, Xiao M, Chang, Yang F, Dela Cruz CS, Wang Y, Wu C, Xiao Y,
- Zhang L, Han L, Dang S, Xu Y, Yang QW, Xu SY, Zhu HD, Xu YC, Jin Q, Shama L,
- Wang L, Wang J. 2020. Profiling early humoral response to diagnose novel
- 431 coronavirus disease (COVID-19). Clin Infect Dis 71:778–785.
- 432 12. To KK, Tsang OT, Leung WS, Tam AR, Wu TC, Lung DC, Yip CC, Cai JP, Chan JM,
- Chik TS, Lau DP, Choi CY, Chen LL, Chan WM, Chan KH, Ip JD, Ng AC, Poon RW, Luo
- 434 CT, Cheng VC, Chan JF, Hung IF, Chen Z, Chen H, Yuen KY. 2020. Temporal profiles
- of viral load in posterior oropharyngeal saliva samples and serum antibody responses
- during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis
- 437 20:565–574.
- 438 13. Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, Liao P, Qiu JF, Lin Y, Cai XF,
- Wang DQ, Hu Y, Ren JH, Tang N, Xu YY, Yu LH, Mo Z, Gong F, Zhang XL, Tian WG,
- Hu L, Zhang XX, Xiang JL, Du HX, Liu HW, Lang CH, Luo XH, Wu SB, Cui XP, Zhou Z,
- Zhu MM, Wang J, Xue CJ, Li XF, Wang L, Li ZJ, Wang K, Niu CC, Yang QJ, Tang XJ,
- Zhang Y, Liu XM, Li JJ, Zhang DC, Zhang F, Liu P, Yuan J, Li Q, Hu JL, Chen J, et al.
- 443 2020. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med
- 444 26:845–848.
- 445 14. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, Wang X, Yuan J, Li T, Li J, Qian S,
- 446 Hong C, Wang F, Liu Y, Wang Z, He Q, Li Z, He B, Zhang T, Fu Y, Ge S, Liu L, Zhang
- J, Xia N, Zhang Z. 2020. Antibody responses to SARS-CoV-2 in patients with novel
- 448 coronavirus disease 2019. Clin Infect Dis 71:2027–2034.
- 449 15. Lou B, Li TD, Zheng SF, Su YY, Li ZY, Liu W, Yu F, Ge SX, Zou QD, Yuan Q, Lin S,
- Hong CM, Yao XY, Zhang XJ, Wu DH, Zhou GL, Hou WH, Li TT, Zhang YL, Zhang SY,
- 451 Fan J, Zhang J, Xia NS, Chen Y. 2020. Serology characteristics of SARS-CoV-2
- infection after exposure and post-symptom onset. Eur Respir J 56.
- 453 16. Young BE, Ong SWX, Ng LFP, Anderson DE, Chia WN, Chia PY, Ang LW, Mak TM,
- Kalimuddin S, Chai LYA, Pada S, Tan SY, Sun L, Parthasarathy P, Fong SW, Chan YH,
- Tan CW, Lee B, Rötzschke O, Ding Y, Tambyah P, Low JGH, Cui L, Barkham T, Lin
- 456 RTP, Leo YS, Renia L, Wang LF, Lye DC. 2020. Viral dynamics and immune correlates
- of COVID-19 disease severity. Clin Infect Dis doi:10.1093/cid/ciaa1280.
- 458 17. Kontou PI, Braliou GG, Dimou NL, Nikolopoulos G, Bagos PG. 2020. Antibody tests in
- detecting SARS-CoV-2 infection: A meta-analysis. Diagnostics (Basel) 10:319.

- 460 18. Ernst E, Wolfe P, Stahura C, Edwards KA. 2021. Technical considerations to
- development of serological tests for SARS-CoV-2. Talanta 224:121883.
- 462 19. Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, Li JX, Yang BF, Wang L, Wang
- WJ, Wu SP, Wang Z, Wu XH, Xu JJ, Zhang Z, Jia SY, Wang BS, Hu Y, Liu JJ, Zhang J,
- 464 Qian XA, Li Q, Pan HX, Jiang HD, Deng P, Gou JB, Wang XW, Wang XH, Chen W.
- 465 2020. Immunogenicity and safety of a recombinant adenovirus type-5-vectored
- 466 COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-
- blind, placebo-controlled, phase 2 trial. Lancet 396:479–488.
- 468 20. Widge AT, Rouphael NG, Jackson LA, Anderson EJ, Roberts PC, Makhene M, Chappell
- JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott AB, Flach B, Lin BC, Doria-
- 470 Rose NA, O'Dell S, Schmidt SD, Neuzil KM, Bennett H, Leav B, Makowski M, Albert J,
- 471 Cross K, Edara VV, Floyd K, Suthar MS, Buchanan W, Luke CJ, Ledgerwood JE,
- 472 Mascola JR, Graham BS, Beigel JH. 2021. Durability of Responses after SARS-CoV-2
- 473 mRNA-1273 Vaccination. N Engl J Med 384:80–82.
- 474 21. World Health Organization. 2021. The COVID-19 candidate vaccine landscape.
- 475 https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-
- 476 <u>vaccines</u>. Accessed February 09 2021.
- 477 22. The New York Times. 2021. Coronavirus vaccine tracker.
- 478 https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html.
- 479 Accessed February 09 2021.
- 480 23. Dai L, Gao GF. 2020. Viral targets for vaccines against COVID-19. Nat Rev Immunol
- 481 doi:10.1038/s41577-020-00480-0.
- 482 24. Forni G, Mantovani A. 2021. COVID-19 vaccines: where we stand and challenges
- 483 ahead. Cell Death Differ doi:10.1038/s41418-020-00720-9:1-14.
- 484 25. Ni L, Ye F, Cheng ML, Feng Y, Deng YQ, Zhao H, Wei P, Ge J, Gou M, Li X, Sun L,
- 485 Cao T, Wang P, Zhou C, Zhang R, Liang P, Guo H, Wang X, Qin CF, Chen F, Dong C.
- 486 2020. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19
- 487 convalescent individuals. Immunity 52:971–977 e3.
- 488 26. Roche Diagnostics GmbH. 2020. Elecsys® Anti-SARS-CoV-2 S assay method sheet;
- V1. https://diagnostics.roche.com/global/en/products/params/elecsys-anti-sars-cov-
- 490 <u>2-s.html</u>. Accessed February 26 2021.
- 491 27. Roche Diagnostics GmbH. 2020. Elecsys® Anti-SARS-CoV-2 assay method sheet;
- 492 09203095501 V6.0. https://www.fda.gov/media/137605/download. Accessed
- 493 February 26 2021.

- 494 28. DiaSorin. 2020. LIAISON® SARS-CoV-2 S1/S2 IgG assay method sheet;
- 495 M0870004366/D 09/20.
- 496 https://www.diasorin.com/sites/default/files/allegati_prodotti/covid_-
- 497 <u>brochure igg unica m0870004366-d low.pdf</u>. Accessed February 26 2021.
- 498 29. EUROIMMUN. 2020. Anti-SARS-CoV-2 ELISA (IgG) product data sheet;
- 499 EI 2606 D UK A06, 10/2020. https://www.coronavirus-
- diagnostics.com/documents/Indications/Infections/Coronavirus/EI 2606 D UK A.pdf
- 501 . Accessed February 26 2021.
- 502 30. EUROIMMUN. 2020. Anti-SARS-CoV-2 ELISA (IgA) product data sheet;
- 503 EI 2606 D UK B04, 10/2020. https://www.coronavirus-
- diagnostics.com/documents/Indications/Infections/Coronavirus/EI_2606_D_UK_B.pdf
- 505 . Accessed February 26 2021.
- 506 31. Abbott. 2020. ARCHITECT SARS-CoV-2 IgG assay method sheet.
- 507 https://www.fda.gov/media/137383/download. Accessed February 26 2021.
- 508 32. Siemens. 2020. ADVIA Centaur® SARS-CoV-2 Total (COV2T) assay method sheet;
- 509 11206904_EN Rev. 01, 2020-05. https://www.fda.gov/media/138446/download.
- Accessed February 26 2021.
- 511 33. Shenzhen YHLO Biotech Co Ltd. 2020. iFlash-SARS-CoV-2 IgM/IgG antibody test
- 512 product overview. http://en.szyhlo.com/cmscontent/iFlash-SARS-CoV-2-IgMIgG-
- 513 Antibody-Test-439.html, Accessed February 26 2021.
- 514 34. Hajian-Tilaki K. 2014. Sample size estimation in diagnostic test studies of biomedical
- informatics. J Biomed Inform 48:193–204.
- 516 35. R Core Team. 2017. R: A language and environment for statistical computing. R
- 517 Foundation for Statistical Computing, Vienna, Austria. https://www.R-project.org/.
- 518 Accessed February 26 2021.
- 519 36. Wenzel D, Zapf A. 2013. Difference of two dependent sensitivities and specificities:
- 520 Comparison of various approaches. Biom J 55:705–718.
- 521 37. Premkumar L, Segovia-Chumbez B, Jadi R, Martinez DR, Raut R, Markmann A,
- 522 Cornaby C, Bartelt L, Weiss S, Park Y, Edwards CE, Weimer E, Scherer EM, Rouphael
- N, Edupuganti S, Weiskopf D, Tse LV, Hou YJ, Margolis D, Sette A, Collins MH,
- 524 Schmitz J, Baric RS, de Silva AM. 2020. The receptor binding domain of the viral
- 525 spike protein is an immunodominant and highly specific target of antibodies in SARS-
- 526 CoV-2 patients. Sci Immunol 5.
- 527 38. Muench P, Jochum S, Wenderoth V, Ofenloch-Haehnle B, Hombach M, Strobl M,
- 528 Sadlowski H, Sachse C, Torriani G, Eckerle I, Riedel A. 2020. Development and

- validation of the Elecsys Anti-SARS-CoV-2 immunoassay as a highly specific tool for
- determining past exposure to SARS-CoV-2. J Clin Microbiol 58.
- 531 39. Dashraath P, Wong JLJ, Lim MXK, Lim LM, Li S, Biswas A, Choolani M, Mattar C, Su
- LL. 2020. Coronavirus disease 2019 (COVID-19) pandemic and pregnancy. Am J
- 533 Obstet Gynecol 222:521–531.
- 534 40. Farnsworth CW, Anderson NW. 2020. SARS-CoV-2 serology: much hype, little data.
- 535 Clin Chem 66:875–877.
- 536 41. Meyer B, Torriani G, Yerly S, Mazza L, Calame A, Arm-Vernez I, Zimmer G, Agoritsas
- T, Stirnemann J, Spechbach H, Guessous I, Stringhini S, Pugin J, Roux-Lombard P,
- Fontao L, Siegrist CA, Eckerle I, Vuilleumier N, Kaiser L, Geneva Center for Emerging
- 539 Viral D. 2020. Validation of a commercially available SARS-CoV-2 serological
- immunoassay. Clin Microbiol Infect 26:1386–1394.
- 541 42. Kohmer N, Westhaus S, Ruhl C, Ciesek S, Rabenau HF. 2020. Brief clinical evaluation
- of six high-throughput SARS-CoV-2 IgG antibody assays. J Clin Virol 129:104480.
- 543 43. Okba NMA, Muller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VM, Lamers MM,
- 544 Sikkema RS, de Bruin E, Chandler FD, Yazdanpanah Y, Le Hingrat Q, Descamps D,
- Houhou-Fidouh N, Reusken C, Bosch BJ, Drosten C, Koopmans MPG, Haagmans BL.
- 546 2020. Severe acute respiratory syndrome coronavirus 2-specific antibody responses
- in coronavirus disease patients. Emerg Infect Dis 26:1478–1488.
- 548 44. Ocmant A, Roisin S, De Meuter R, Brauner J. 2021. Clinical performance of the Advia
- 549 Centaur anti-SARS-CoV-2 chemiluminescent immunoassay related to antibody
- kinetics. J Med Virol doi:10.1002/jmv.26800.
- 551 45. Oved K, Olmer L, Shemer-Avni Y, Wolf T, Supino-Rosin L, Prajgrod G, Shenhar Y,
- 552 Payorsky I, Cohen Y, Kohn Y, Indenbaum V, Lazar R, Geylis V, Oikawa MT, Shinar E,
- 553 Stoyanov E, Keinan-Boker L, Bassal R, Reicher S, Yishai R, Bar-Chaim A, Doolman R,
- Reiter Y, Mendelson E, Livneh Z, Freedman LS, Lustig Y. 2020. Multi-center
- nationwide comparison of seven serology assays reveals a SARS-CoV-2 non-
- responding seronegative subpopulation. EClinicalMedicine 29:100651.
- 557 46. Burbelo PD, Riedo FX, Morishima C, Rawlings S, Smith D, Das S, Strich JR, Chertow
- 558 DS, Davey RT, Jr., Cohen JI. 2020. Detection of nucleocapsid antibody to SARS-CoV-
- 2 is more sensitive than antibody to spike protein in COVID-19 patients. medRxiv
- 560 doi:10.1101/2020.04.20.20071423.
- 561 47. Wang Y, Zhang L, Sang L, Ye F, Ruan S, Zhong B, Song T, Alshukairi AN, Chen R,
- Zhang Z, Gan M, Zhu A, Huang Y, Luo L, Mok CKP, Al Gethamy MM, Tan H, Li Z,
- Huang X, Li F, Sun J, Zhang Y, Wen L, Li Y, Chen Z, Zhuang Z, Zhuo J, Chen C,

564 Kuang L, Wang J, Lv H, Jiang Y, Li M, Lin Y, Deng Y, Tang L, Liang J, Huang J, 565 Perlman S, Zhong N, Zhao J, Malik Peiris JS, Li Y, Zhao J. 2020. Kinetics of viral load 566 and antibody response in relation to COVID-19 severity. J Clin Invest 130:5235-567 5244. 568 48. Van Elslande J, Decru B, Jonckheere S, Van Wijngaerden E, Houben E, 569 Vandecandelaere P, Indevuyst C, Depypere M, Desmet S, Andre E, Van Ranst M, 570 Lagrou K, Vermeersch P. 2020. Antibody response against SARS-CoV-2 spike protein 571 and nucleoprotein evaluated by four automated immunoassays and three ELISAs. 572 Clin Microbiol Infect 26:1557 e1-1557 e7. 573 49. Johnson M, Wagstaffe HR, Gilmour KC, Mai AL, Lewis J, Hunt A, Sirr J, Bengt C, 574 Grandjean L, Goldblatt D. 2020. Evaluation of a novel multiplexed assay for 575 determining IgG levels and functional activity to SARS-CoV-2. J Clin Virol 576 130:104572. 577

Table 1. Specificity results for the Elecsys Anti-SARS-CoV-2 S assay

Sample cohort		Number of	Reactive	Specificity (95% confidence
		samples	samples	intervals, 2-sided)
Blood donors				
	Innsbruck / influenza season	1050	1	99.90% (99.47–100.00)
Origin /	Hagen / no seasonal selection	955	0	100.00% (99.61–100.00)
season	Bern / outside influenza season	2000	2	99.90% (99.64–99.99)
	Bern / influenza season	1051	0	100.00% (99.65-100.00)
Total blood donors		5056	3	99.94% (99.83–99.99)
Diagnostic ro	utine			
	Augsburg / diagnostic routine	400	0	100.00% (99.08-100.00)
Origin / cohort	Augsburg / pregnancy screening	1496	1	99.93% (99.63–100.00)
	Heidelberg / pregnancy screening	737	0	100.00% (99.50-100.00)
	Heidelberg / pediatric samples	191	0	100.00% (98.09–100.00)
Total diagnostic routine		2824	1	99.96% (99.80–100.00)
Overall (all sa	mples)	7880	4	99.95% (99.87–99.99)

Table 2a. Overall sensitivity results for the Elecsys Anti-SARS-CoV-2 S assay

Days post-PCR-positive test	Number of	Reactive	Non-reactive	Sensitivity (95% confidence
	samples	samples	samples	intervals, 2-sided)
0 to 6	44	25	19	56.82% (41.03–71.65)
7 to 13	49	42	7	85.71% (72.76–94.06)
14 to 20	47	46	1	97.87% (88.71–99.95)
21 to 27	58	58	0	100.00% (93.84–100.00)
28 to 34	43	43	0	100.00% (91.78–100.00)
35 to 41	57	56	1	98.25% (90.61–99.96)
42 to 48	47	47	0	100.00% (92.45–100.00)
49 to 55	39	35	4	89.74% (75.78–97.13)
56 to 62	33	33	0	100.00% (89.42–100.00)
≥63 (up to 120)	21	21	0	100.00% (83.89–100.00)
All samples ≥14 (up to 120)¹	240	235	5	97.92% (95.21–99.32)

⁵⁸¹ Only the last sample taken \geq 14 days post-PCR of each patient is included in the sensitivity calculation.

PCR, polymerase chain reaction

580

583

587

Table 2b. Sensitivity results for the Elecsys Anti-SARS-CoV-2 S assay per site

Days post-	Augsburg		Berlin		Heidelberg		Regensburg	
PCR-positive	N	Sensitivity	N	Sensitivity	N	Sensitivity	N	Sensitivity
test		(95% CI)		(95% CI)		(95% CI)		(95% CI)
0 to 6	3	33.33%	23	60.87%	18	55.56%	0	N/A
		(0.84–90.57)		(38.54-80.29)		(30.76-78.47)		
7 to 13	4	100.00%	34	85.29%	11	81.82%	0	N/A
		(39.76–100.00)		(68.94–95.05)		(48.22–97.72)		
≥14 (up to 120) ¹	88	100.00%	41	100.00%	78	98.72%	33	87.88%
		(95.89-100.00)		(91.40-100.00)		(93.06–99.97)		(71.80–96.60)

⁵⁸⁵ 1 Only the last sample taken \geq 14 days post-PCR of each patient is included in the sensitivity calculation.

CI, confidence interval; N, number of samples; N/A, not applicable; PCR, polymerase chain reaction

Table 3. Specificity of the Elecsys Anti-SARS-CoV-2 S assay and other comparator assays

Assay	Number of	Reactive	Non-reactive	Specificity (95% confidence
	samples	samples	sa mples	intervals, 2-sided)
LIAISON SARS-CoV-2 S1/S2 IgG (GZ excl.) ¹	2033	24	2009	98.82% (98.25–99.24)
Elecsys Anti-SARS-CoV-2 S	2033	1	2032	99.95% (99.73–100.00)
LIAISON SARS-CoV-2 S1/S2 IgG (GZ+)	2040	31	2009	98.48% (97.85–98.97)
Elecsys Anti-SARS-CoV-2 S	2010	1	2039	99.95% (99.73–100.00)
ADVIA Centaur SARS-CoV-2 Total	928	121	807	86.96% (84.62–89.06)
Elecsys Anti-SARS-CoV-2 S	320	0	928	100.00% (99.60-100.00)
ARCHITECT SARS-CoV-2 IgG	2932	9	2923	99.69% (99.42–99.86)
Elecsys Anti-SARS-CoV-2 S	2332	1	2931	99.97% (99.81–100.00)
EUROIMMUN Anti-SARS-CoV-2 IgG (GZ excl.)	903	23	880	97.45% (96.20–98.38)
Elecsys Anti-SARS-CoV-2 S	303	0	903	100.00% (99.59–100.00)
EUROIMMUN Anti-SARS-CoV-2 IgG (GZ+)	924	44	880	95.24% (93.66–96.52)
Elecsys Anti-SARS-CoV-2 S	32.1	0	924	100.00% (99.60-100.00)
EUROIMMUN Anti-SARS-CoV-2 IgA (GZ excl.)	895	38	857	95.75% (94.22–96.98)
Elecsys Anti-SARS-CoV-2 S	033	0	895	100.00% (99.59–100.00)
EUROIMMUN Anti-SARS-CoV-2 IgA (GZ+)	928	71	857	92.35% (90.45–93.98)
Elecsys Anti-SARS-CoV-2 S	320	0	928	100.00% (99.60-100.00)
iFlash-SARS-CoV-2 IgG	928	0	928	100.00% (99.60–100.00)
Elecsys Anti-SARS-CoV-2 S		0	928	100.00% (99.60–100.00)
iFlash-SARS-CoV-2 IgM	928	4	924	99.57% (98.90–99.88)
Elecsys Anti-SARS-CoV-2 S	720	0	928	100.00% (99.60-100.00)

¹For antibody assays with a gray zone, two calculations were performed. In the first calculation, all gray zone results were excluded from the analysis (GZ excl.) and in the second calculation these results were interpreted as

reactive (GZ+).

588

592 GZ, gray zone

Table 4. Sensitivity of the Elecsys Anti-SARS-CoV-2 S assay and other comparator assays

Assay	Days post-PCR-	Total	Non-reactive	Sensitivity (95% confidence	
	positive test	samples	samples	intervals, 2-sided)	
ADVIA Centaur SARS-CoV-2 Total	0.6	10	8	55.56% (30.76–78.47)	
	0–6	18	8	55.56% (30.76–78.47)	
Elecsys Anti-SARS-CoV-2 S		11	2	81.82% (48.22–97.72)	
	7–13		2	81.82% (48.22–97.72)	
			4	94.81% (87.23–98.57)	
	≥14	77	1	98.70% (92.98–99.97)	
ARCHITECT SARS-CoV-2 IgG			9	50.00% (26.02–73.98)	
	0–6	18	8	55.56% (30.76–78.47)	
Elecsys Anti-SARS-CoV-2 S			2	81.82% (48.22–97.72)	
	7–13	11	2	81.82% (48.22–97.72)	
			10	87.01% (77.41–93.59)	
	≥14	77	1	98.70% (92.98–99.97)	
EUROIMMUN Anti-SARS-CoV-2 IgG	g G 0–6	43	21	51.16% (35.46–66.69)	
(GZ excl.) ¹			18	58.14% (42.13–72.99)	
		45	7	84.44% (70.54–93.51)	
Elecsys Anti-SARS-CoV-2 S	7–13		7	84.44% (70.54–93.51)	
		115	7	93.91% (87.86–97.52)	
	≥14		2	98.26% (93.86–99.79)	
EUROIMMUN Anti-SARS-CoV-2 IgG			21	52.27% (36.69–67.54)	
(GZ+)	0–6	44	19	56.82% (41.03–71.65)	
			7	85.71% (72.76–94.06)	
Elecsys Anti-SARS-CoV-2 S	7–13	49	7	85.71% (72.76–94.06)	
		119	6	94.96% (89.35–98.13)	
	≥14		1	99.16% (95.41–99.98)	
EUROIMMUN Anti-SARS-CoV-2 IgA			18	59.09% (43.25–73.66)	
(GZ excl.)	0–6	44	19	56.82% (41.03–71.65)	
/			4	91.84% (80.40–97.73)	
Elecsys Anti-SARS-CoV-2 S	7–13	49	7	85.71% (72.76–94.06)	
Electro Alla DARO-COV-2 3			/	03.7170 (72.70-34.00)	

	≥14	118	3	97.46% (92.75–99.47)
	214	110	1	99.15% (95.37–99.98)
EUROIMMUN Anti-SARS-CoV-2 IgA	0–6	44	18	59.09% (43.25–73.66)
(GZ+)	0-6	44	19	56.82% (41.03–71.65)
	7 12	40	4	91.84% (80.40–97.73)
Elecsys Anti-SARS-CoV-2 S	7–13	49	7	85.71% (72.76–94.06)
	≥14	424	3	97.52% (92.93–99.49)
		121	1	99.17% (95.48–99.98)
iFlash-SARS-CoV-2 IgG		47	8	52.94% (27.81–77.02)
	0–6	17	7	58.82% (32.92–81.56)
Elecsys Anti-SARS-CoV-2 S	- 40		2	81.82% (48.22–97.72)
	7–13	11	2	81.82% (48.22–97.72)
	S-4.4	76	5	93.42% (85.31–97.83)
	≥14	76	0	100.00% (95.26–100.00)
iFlash-SARS-CoV-2 IgM	0.6	47	11	35.29% (14.21–61.67)
	0–6	17	7	58.82% (32.92–81.56)
Elecsys Anti-SARS-CoV-2 S	7.40	11	9	18.18% (2.28–51.78)
	7–13	11	2 81.82% (48.22–97.7	81.82% (48.22–97.72)
	>14	76	49	35.53% (24.88–47.34)
	≥14	76	0	100.00% (95.26–100.00)

¹For antibody assays with a gray zone, two calculations were performed. In the first calculation, all gray zone results were excluded from the analysis (GZ excl.) and in the second calculation these results were interpreted as reactive (GZ+).

598 GZ, gray zone




Figure 1. Longitudinal antibody titers of all subjects. Concentration of anti-S SARS-CoV-2 antibodies, as measured by the Elecsys Anti-S SARS-CoV-2 S immunoassay, over time (days 0 to 78) in sequential samples from all study sites. Each grey circle represents a different data point, with darker circles representing overlapping data points. The solid blue line represents the combined curve and the blue dashed lines represent the upper and lower confidence limits. The red dashed line indicates the assay cutoff limit (0.80 U/mL).